(a) In making a decision regarding the placement of a drug on each of the preferred drug lists adopted under this subchapter, the commission shall consider:
(1) the board’s recommendations under § 549.0309;
(2) the drug’s clinical efficacy;
(3) the price of competing drugs after deducting any federal and state rebate amounts; and
(4) program benefit offerings solely or in conjunction with rebates and other pricing information.
(b) The commission shall consider including on a preferred drug list:
(1) multiple methods of delivery within each drug class, including liquid, capsule, and tablet, including an orally disintegrating tablet; and
(2) all strengths and dosage forms of a drug.

Text of section effective on April 01, 2025